Showing 1 to 2 of 2 results


Losartan Shows Promise for Butterfly Skin, but Funding for Clinical Trial Remains a Challenge
Losartan, a hypertension drug, shows promise in treating epidermolysis bullosa (butterfly skin) lesions, but a €5-10 million clinical trial is needed for EMA approval, highlighting challenges in repurposing drugs for rare diseases.
Losartan Shows Promise for Butterfly Skin, but Funding for Clinical Trial Remains a Challenge
Losartan, a hypertension drug, shows promise in treating epidermolysis bullosa (butterfly skin) lesions, but a €5-10 million clinical trial is needed for EMA approval, highlighting challenges in repurposing drugs for rare diseases.
Progress
36% Bias Score

FDA Approves First Gene Therapy for RDEB, Showcasing Innovative Funding Model
The FDA approved ZEVASKYN, the first autologous cell-based gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a significant advancement driven by EB Research Partnership's innovative venture philanthropy model, offering hope to 500,000 people globally.

FDA Approves First Gene Therapy for RDEB, Showcasing Innovative Funding Model
The FDA approved ZEVASKYN, the first autologous cell-based gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a significant advancement driven by EB Research Partnership's innovative venture philanthropy model, offering hope to 500,000 people globally.
Progress
52% Bias Score
Showing 1 to 2 of 2 results